Key Takeaways for 2026 Dental Practice Sales
- DSO demand remains strong in 2026, with 69% of groups planning increased acquisitions and multiples near historic highs for well-prepared sellers.
- Adjusted EBITDA is the key valuation metric, and only defensible, normalized earnings survive buyer due diligence and support upper-range multiples.
- Practice size, hygiene production, associate-led revenue, payer mix, and infrastructure can be some of the main factors that shift multiples by 0.5x to 4x.
- Owners who run a competitive, multi-buyer process and prepare financials in advance often realize 20–30% higher valuations than those negotiating alone.
- McLerran & Associates delivers a diligence-grade, CPA-led valuation and runs a structured auction process that aims to maximize outcomes. Request a confidential discovery call to explore your options.
Adjusted EBITDA: The Number Buyers Actually Pay For
Adjusted EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is the earnings figure DSO and private equity buyers use to value practices. In this context, it is normalized for owner-specific expenses and non-recurring items. Adjusted EBITDA reflects the cash flow a new owner can reasonably expect after paying a market-rate salary to replace the selling dentist and removing personal or one-time costs. This number drives the multiple and, as a result, the price a buyer is willing to pay.
2026 EBITDA Multiple Ranges by Practice Size
Once adjusted EBITDA is clear, the next step is understanding how multiples vary by practice size and buyer profile. The table below reflects ranges drawn from multiple 2026 market sources. These are ranges, not guarantees. Your specific multiple depends on the value drivers discussed below, the buyer pool created, and the quality of your normalized EBITDA analysis.
| Practice Tier | Adjusted EBITDA Range | Indicative Multiple Range | Typical Buyer Profile |
|---|---|---|---|
| Small / Solo Add-On | Smaller practices | Lower range | Corporate tuck-in, where associate coverage and hygiene mix begin to move the multiple |
| Established Group / Add-On | Mid-sized groups | Mid-to-upper range | Most competitive band, where both corporate add-on and emerging-platform buyers submit LOIs |
| Emerging Platform | Larger practices | Higher range | Private equity platform recap candidates, often multi-location regional groups with specialty mix |
| Platform-Grade | $5M+ | 10x to 12x+ | Private equity-backed corporate platforms, typically large multi-site groups with management infrastructure |
Specialty practices can command a meaningful premium over general dentistry at comparable size tiers. That premium often falls in the range of 1 to 3 additional turns of EBITDA and is driven by higher per-procedure revenue, durable referral networks, and differentiated buyer demand. Practices with lower adjusted EBITDA are often priced on seller’s discretionary earnings or a percentage of collections rather than a pure EBITDA multiple, because many corporate buyers have minimum size thresholds.
How EBITDA Multiples Work in Dental Practice Valuations
The EBITDA multiple applied to your practice functions as a range rather than a fixed number. It reflects the quality and defensibility of your normalized earnings, the depth of the buyer pool competing for your practice, and the value drivers described below. A strong multiple still depends on a reliable EBITDA figure underneath it.
McLerran & Associates builds each valuation from the ground up using a CPA-led process. The team remotely accesses the practice’s management software, cross-references production and collection data against financial statements, and unpacks every discretionary, personal, and non-recurring expense to arrive at a defensible adjusted EBITDA figure. Aggressive or unsupportable add-backs are the single most common reason a deal drops in price during due diligence. McLerran completes this diligence-grade work before the practice goes to market, so the number tends to hold when buyers scrutinize it and deals are less likely to be re-traded at the finish line.
Calculating What Your Dental Practice May Be Worth
For DSO and private equity transactions, practice value is commonly calculated as: Adjusted EBITDA × Market Multiple = Enterprise Value. Reaching a defensible adjusted EBITDA usually requires a structured normalization process.
The most common and significant add-backs include:
- Owner compensation above market rate. Owners normalize EBITDA by replacing actual owner compensation with fair-market dentist compensation. This adjustment is often the largest single add-back in dental valuations.
- Personal expenses run through the practice. Personal expenses routinely added back typically total $30K to $150K per year. Examples include vehicle expenses, family member compensation without a genuine business function, club memberships, personal travel labeled as continuing education, and excessive meals and entertainment.
- One-time and non-recurring costs. One-time non-recurring expenses such as emergency equipment replacement, litigation settlements, or unusual facility repairs are often accepted as add-backs when genuinely non-recurring. Buyers typically review multiple years of financials to verify that these items do not repeat.
- Above-market related-party rent. When a practice owner also owns the building, rent is normalized to market rates, often 5–7% of collections. Below-market rent can create a negative adjustment.
- Non-arms-length family compensation. Only the above-market portion of family member compensation typically qualifies as an add-back. The market-rate cost of the role usually remains in the expense base.
Defending these add-backs through a buyer’s quality-of-earnings review usually requires documentation, consistency across multiple years of financials, and an advisor who has completed this work many times. McLerran’s CPA-led process produces a number that most accountants would recognize as carefully prepared and defensible. Once that figure is clear, the next step is understanding which buyer market may value it most favorably.
Corporate vs. Private-Buyer Valuation Paths
The same practice can command materially different valuations depending on whether the buyer is a DSO or an individual dentist. Understanding both paths can help owners choose a direction that fits their goals.
Solo doctor or private-buyer transactions are often quoted as a percentage of annual collections rather than an EBITDA multiple. Typical ranges fall around 60% to 80% of trailing 12-month collections for SBA-financed deals. A practice generating $1.5M in collections might attract a private-buyer offer in the range of $900K to $1.2M.
A corporate buyer evaluating the same practice on adjusted EBITDA, assuming a 20% normalized EBITDA margin or $300K in adjusted EBITDA, would apply a multiple from the applicable tier. At 5x to 7x, that produces an enterprise value of $1.5M to $2.1M. Corporate platforms backed by private equity can often pay more than individual dentist buyers for larger practices, supported by cheaper institutional capital, roll-up exit strategies, and platform-level cost savings.
For practices in the $1.5M to $3M revenue range, both paths can be viable. Because McLerran works private-buyer and corporate transactions in roughly equal measure, it can produce a side-by-side valuation so owners compare their worth in both markets before deciding.
Key Value Drivers That Can Move Multiples in 2026
Within any EBITDA tier, specific practice characteristics can push a practice toward the top or bottom of its multiple range, or even move it into a different tier.
Factors that can support a higher multiple include:
- Hygiene production above 30% of collections. Practices with hygiene revenue above 30% of collections can receive a +0.5x to +1.0x multiple premium, because recurring hygiene visits signal a stable, transferable patient base.
- Associate-led production. Practices where the owner-doctor performs below 70% of chair time can receive a +0.5x to +1.5x multiple uplift. Owner production above 90% can trigger a 10–20% valuation reduction.
- Multi-location scale. Multi-location regional clusters of 3 or more offices with shared management infrastructure can command a +2x to +4x platform premium over single-location add-ons.
- Balanced, commercial-heavy payer mix. Fee-for-service-heavy practices can average a 15–25% premium on enterprise value compared with PPO-heavy practices.
- Modern technology and infrastructure. Deferred technology investment, such as aging operatories without cone-beam CT, digital impressions, or modern sterilization equipment, can signal a $100K to $500K post-close upgrade liability that compresses multiples by 0.25x to 0.5x.
- Documented systems and KPI dashboards. A trained, non-owner management team with written systems and KPI dashboards can add 1x to 3x EBITDA by reducing reliance on personal goodwill and supporting upper-range multiples.
Factors that can compress a multiple include:
- Medicaid or HMO concentration above 40% of collections, which can compress multiples by 0.5x to 1.0x
- Provider concentration where one doctor drives a disproportionate share of production, which became a primary decision driver for corporate acquirers in 2026 and was a leading reason buyers walked away from deals in 2025
- Lease terms with fewer than 5 years remaining
- Open compliance citations or unresolved payer audits, which can reduce valuation by 5–20%
Steps to Improve Your Multiple Before Going to Market
Thoughtful pre-sale preparation can meaningfully shift where a practice lands within its multiple range. McLerran & Associates often recommends the following sequence before going to market:
- Clean discretionary expenses. Identify and document every personal or non-recurring expense running through the practice so add-backs are defensible, not improvised under buyer scrutiny.
- Document add-backs with supporting evidence. Once those expenses are identified, document each add-back with payroll records, receipts, and market compensation analyses that can withstand a quality-of-earnings review.
- Stabilize provider contracts. Beyond the financials, associate and hygienist retention agreements reduce transition risk and support the upper end of the multiple range. DSOs are now commonly requiring a minimum 5-year post-close employment term and are increasingly walking away from deals due to insufficient staffing and over-reliance on a single producer.
- Strengthen hygiene recall systems. Next, focus on documented recall adherence and hygienist productivity metrics, which are among the first items DSO underwriters review.
- Address deferred capital expenditure. Finally, modernizing operatories or digital workflows before going to market can remove a buyer’s justification for a valuation discount.
Red Flags to Watch for in Corporate Offers
Not every corporate offer deserves serious consideration, and some terms can quietly reduce the real value of a deal. Owners can watch for several common warning signs.
- Punitive earnout structures. An earnout, which is a portion of the purchase price paid only if the practice hits future performance targets, is common. Terms can vary widely. Earnouts with no pro-rata provision, unrealistic targets, or a start date that begins immediately after close can effectively reduce the real purchase price by hundreds of thousands of dollars.
- Equity in undercapitalized platforms. Rising interest rates, higher operating costs, and heavy leverage have placed new pressure on corporate balance sheets, and some platforms have moved into lender control after financial restructuring challenges. As much as 40% of a corporate deal can be paid in equity, so partnering with an undercapitalized platform can put a significant share of the owner’s proceeds at risk.
- A single offer with no competitive process. A corporate buyer that approaches an owner directly has little incentive to offer the strongest terms. Without competing bids, there is no market reference and limited leverage for negotiation.
- Weak or unverifiable buyer financials. Owners can treat the corporate buyer’s equity as an investment and review the platform’s profitability, growth trajectory, management team, and private equity backing before accepting any offer.
How Competitive Sale Processes Lift Outcomes
Creating genuine competition among multiple, well-qualified buyers is one of the most reliable ways to reach the upper end of a practice’s multiple range. McLerran & Associates runs a structured, auction-like bid process, typically 45 to 60 days, that often generates around 10 offers per listing from a vetted pool of buyers. Weaker platforms are screened out before they reach the table.
Several recent engagements illustrate this approach. When Dr. William Pena engaged McLerran to represent his seven-location pediatric group, there were already offers on the table. McLerran’s CPA-led EBITDA analysis and competitive process produced a valuation roughly 20% higher than those initial offers. When Dr. Rob Gatewood and his partner needed a corporate buyer because no single dentist could acquire their highly productive practice, McLerran generated eight competing offers, and the owners used that competition to maximize value and select a group they viewed as a strong fit. When Dr. Mark Sweeney, who had built one of Austin’s premier practices over more than 40 years, was ready to plan his succession, McLerran generated six offers from fully vetted buyers and provided the information and leverage he needed to choose the partner that made him most comfortable.
These outcomes reflect a defensible EBITDA number, a broad and vetted buyer pool, and a structured process that creates the competitive tension needed to push price and terms toward their ceiling.
Recap: A Practical 2026 Valuation Framework
In 2026, DSO multiples for premier dental practices can range from approximately 5x adjusted EBITDA for smaller single-location add-ons to 12x or more for platform-grade multi-site groups. Specialty practices can often command a premium over general dentistry at comparable size tiers. The multiple applied to any individual practice is influenced by the quality of its normalized EBITDA and the strength of its value drivers, including hygiene mix, provider structure, payer mix, infrastructure, and growth trajectory.
Owners who clearly present their adjusted EBITDA, prepare their practices before going to market, and run a structured competitive process among multiple vetted buyers are more likely to reach the upper end of the range. Owners who negotiate alone, or with a single buyer, often see less favorable outcomes.
McLerran & Associates has guided owners through roughly 2,000 successful practice sales and approximately $2 billion in closed transaction volume, with a transaction rate of 85–90%, compared with an industry norm closer to 35–40%. The firm works both private-buyer and DSO transactions in roughly equal measure, produces a diligence-grade CPA-led valuation for every engagement, and runs a competitive process that often lifts valuations well above what owners achieve selling on their own.
Next Step: Clarify Your Practice’s Position
The sale of a dental practice can be one of the largest financial events in a dentist’s career, and a rough estimate from a single buyer rarely tells the full story. Whether you are ready to sell now or simply want to understand what your practice may be worth in today’s market, McLerran & Associates can provide a clear, defensible valuation and a comparison of what both the private-buyer and DSO paths might deliver for your specific practice.
Get a clear, defensible valuation and compare your options by scheduling a confidential discovery call with McLerran & Associates. Call (512) 900-7989 or email info@dentaltransitions.com.
Frequently Asked Questions
How is adjusted EBITDA different from what my accountant reports as net income?
Net income on your tax return or profit-and-loss statement reflects actual expenses as filed, including your full owner compensation, personal expenses run through the practice, one-time costs, and non-cash charges like depreciation and amortization. Adjusted EBITDA starts with that reported figure and adds back expenses that would not exist under a new owner. These can include the portion of your compensation above what a market-rate associate dentist would cost, personal vehicle and travel expenses, family member payroll above the market value of the work performed, one-time repairs or legal fees, and above-market rent paid to an entity you control.
The result is a normalized, transferable earnings figure, which is the cash flow a DSO buyer can underwrite. Because DSO offers are expressed as a multiple of this number, a difference of even $100,000 in adjusted EBITDA can translate into $700,000 to $900,000 or more in enterprise value at a 7x to 9x multiple. The quality and defensibility of the normalization process can therefore matter as much as the multiple itself.
Should I sell to a DSO or to a private buyer (another dentist)?
The right path can depend on your practice’s size, profitability, and your personal goals. Practices in the $1M to $1.5M revenue range often fit a doctor-to-doctor sale well, especially when the owner wants a clean exit and a buyer who will preserve the practice’s culture and patient relationships. Practices above $1.5M in revenue, particularly those with associate producers, multiple locations, or strong EBITDA margins, tend to attract serious DSO interest and can command higher enterprise values through a corporate transaction.
For practices in the $1.5M to $3M revenue range, both directions can be realistic. The better choice usually comes from a side-by-side comparison of what each path delivers in after-tax proceeds over time. Because McLerran & Associates works both markets in roughly equal measure, it can prepare that comparison for each client so the decision rests on real numbers rather than assumptions.
What makes a DSO offer “good” versus one I should walk away from?
A strong DSO offer usually combines a defensible enterprise value, a favorable cash-at-close percentage, equity held at a level of the platform that offers meaningful upside, and earnout terms that are achievable and non-punitive. Examples include a pro-rata provision so a near-miss on an EBITDA target still pays most of the earnout, and a start date that allows time for integration.
Beyond the economics, the quality of the buyer can matter significantly. As much as 40% of a DSO deal can be paid in equity, so partnering with an undercapitalized or poorly managed platform can put a significant share of your proceeds at risk. A good offer typically comes from a well-backed, well-run buyer with a track record of satisfied sellers, and it arrives in a competitive process where you have other qualified offers for comparison. McLerran vets buyers like investments and has blacklisted platforms known for poor post-close environments, so owners in its process see only credible, well-qualified buyers.
How long does the process of selling a dental practice to a DSO typically take?
From the time a practice goes to market to a signed letter of intent, McLerran’s structured bid process typically runs 45 to 60 days and often generates around 10 offers. From a signed LOI through due diligence and closing, the timeline varies by deal complexity but commonly runs an additional 60 to 120 days. The total process from engagement to close is often in the range of 4 to 6 months for a well-prepared practice.
Preparation before going to market, including completing the CPA-led EBITDA analysis, assembling financial documentation, and addressing key pre-sale value drivers, can help keep the process on schedule and reduce the risk of the deal being re-traded during diligence. Owners who attempt to sell without that preparation often find that the timeline extends or that the agreed price erodes when buyers find inconsistencies in the financials.
Is now a good time to sell, or should I wait?
Demand for premier, Class A dental practices remains strong in 2026, with many DSOs reporting that their private equity sponsors expect acquisition activity to increase. Multiples for well-prepared practices are near historic highs for the top tiers. At the same time, buyers are applying more rigorous due diligence than in prior years, and some observers note that multiples have moderated from their 2021–2022 peaks for average-quality assets.
Timing often depends on your specific practice, including its size, profitability, value drivers, and readiness, as much as on broad market conditions. McLerran can provide a candid assessment of where your practice stands today, and if you are not ready to sell, the firm can update your valuation later rather than encourage a transaction before the time feels right.
